Revive Therapeutics Announces Acceptance of Abstract for Cannabinoid Delivery Technology at 29th International Conference on ...
May 10 2018 - 8:00AM
Revive Therapeutics Ltd. ("
Revive" or the
“
Company”) (TSX VENTURE:RVV) (OTCQB:RVVTF), a
company focused on the research, development and commercialization
of novel cannabinoid-based therapies, today announced the
acceptance of an abstract for a poster presentation for the
Company’s cannabinoid delivery technology at the XXIX International
Conference on Polyphenols and the 9th Tannin Conference (“ICP
+ TC 2018”). The poster, entitled “Tannin-Chitosan composite
materials for transdermal delivery of cannabidiol,” detailing the
results from the Company’s research project with the University of
Wisconsin-Madison, will be available for viewing during the poster
sessions.
“We are pleased to have our cannabinoid
delivery technology results presented at this year’s ICP + TC 2018
conference,” said Fabio Chianelli, President of Revive. “Revive is
positioned to advance the development and commercialization of
novel cannabinoid delivery technologies and products offering
licensed medical cannabis producers and pharmaceutical companies
unique opportunities in broad markets opportunities such as in
inflammation, pain, dermatology, wound healing, and liver
disease.”
The XXIX International Conference on Polyphenols
(“ICP”) and the 9th Tannin Conference (“TC”) will be held July
16th through July 20th in Madison, Wisconsin.
Groupe Polyphénols, founded in 1972, is the world’s premier
society of scientists in the fields of polyphenol chemistry,
bioactivity, nutrition, industrial applications, synthesis, and
ecology. Every two years, Groupe Polyphénols hosts the ICP.
The XXIX ICP will be the first one to be held in the United
States. In 2018, the ICP will also host the 9th Tannin
Conference. After the very successful joint meeting in 2014
in Nagoya, the Tannin Conference will continue this new tradition
of meeting jointly with the ICP. This conference coincides
with the 30-year anniversary of the first North American Tannin
Conference, held in Port Angeles Washington in August 1988.
About the Cannabinoid Delivery Technology
The delivery technology aims to deliver both
synthetic cannabinoids and natural extracts of cannabis in a
potential number of ways such as topical gels, creams or ointments,
oral or transdermal patches, and oral dosages. The delivery
technology is a natural, non-toxic, biodegradable and biocompatible
composite that combines a tannin material, which is derived from a
plant group having antibacterial, antifungal, antioxidant and wound
healing properties, and a chitosan material, which is derived from
the crustacean group having blood-clotting and antimicrobial
properties. The delivery technology has rapid onset of action
and controlled or sustained release potential capabilities and may
allow to combine multiple cannabinoids or cannabis extracts in one
formulation. The Company seeks to develop novel products that
target multi-billion dollar market opportunities such as
inflammation, pain (i.e. neuropathic, joint pain), dermatology
(i.e. acne, psoriasis), wound healing applications (i.e. battle
wounds, scarring), and liver diseases.
About Revive Therapeutics
Ltd.
Revive Therapeutics Ltd. (TSX VENTURE:RVV) (OTCQB:RVVTF) is
focused on the research, development and commercialization of novel
cannabinoid-based therapies. Additional information on Revive
is available at www.ReviveThera.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
Neither the TSX-V nor its Regulation Services
Provider (as that term is defined in the policies of the TSX-V)
accepts responsibility for the adequacy or accuracy of this
release.
This news release includes certain information
and statements about management's view of future events,
expectations, plans and prospects that constitute "forward-looking
information" that involves known and unknown risks and
uncertainties, which are not comprised of historical facts, and
most of which are beyond the control of Revive. Forward-looking
statements include estimates and statements that describe Revive’s
future plans, objectives or goals, including words to the effect
that Revive or its management expects a stated condition or result
to occur. Forward-looking statements may be identified by such
terms as "believes", "anticipates", "intends", "expects",
"estimates", "may", "could", "would", "will", or "plan", and
similar expressions. Specifically, forward-looking statements in
this news release include, without limitation, statements
regarding: the granting of a patent for Bucillamine for the
treatment of gout; the potential efficacy and commercial viability
of Bucillamine for treatment of gout and Bucillamine for the
treatment of Cystinuria; expansion of the Bucillamine clinical
testing program; the Company's drug research and development, and
commercialization plans; the Company’s research, development and
commercialization plans for plant-based therapies, including
cannabinoids; the Company’s cannabinoid delivery technology; the
Company’s license agreement with Wisconsin Alumni Research
Foundation; the Company’s cannabinoid-based product pipeline; the
timing of operations; and estimates of market conditions. These
statements involve known and unknown risks, uncertainties, and
other factors that may cause actual results or events, performance,
or achievements of Revive to differ materially from those
anticipated or implied in such forward-looking statements. Since
forward-looking statements are based on assumptions and address
future events and conditions, by their very nature they involve
inherent risks and uncertainties. The Company believes that
the expectations reflected in these forward-looking statements are
reasonable, but there can be no assurance that actual results will
meet management's expectations. In formulating the forward-looking
statements contained herein, management has assumed: that business
and economic conditions affecting Revive will continue
substantially in the ordinary course and will be favourable to
Revive; that clinical testing results will justify
commercialization of the Company's drug candidates; that Revive
will be able to obtain all requisite regulatory approvals to
commercialize its drug candidates; that such approvals will be
received on a timely basis; and, that Revive will be able to find
suitable partners for development and commercialization of its drug
repurposing candidates on favourable terms. Although these
assumptions were considered reasonable by management at the time of
preparation, they may prove to be incorrect and no assurance
can be given that such events will occur in the disclosed time
frames or at all.
Factors that may cause actual results to differ
materially from those anticipated by these forward-looking
statements include: uncertainties associated with obtaining
regulatory approval to perform clinical trials and market products;
the need to establish additional corporate collaborations,
distribution or licensing arrangements; the Company's ability to
raise additional capital if and when necessary; intellectual
property disputes; increased competition from pharmaceutical and
biotechnology companies; changes in equity markets, inflation, and
changes in exchange rates; and other factors as described in detail
in Revive's Management's Discussion & Analysis for the period
ended June 30, 2017 and Revive's other public filings, all of which
may be viewed on SEDAR (www.sedar.com). Given these risks and
uncertainties, readers are cautioned not to place undue reliance on
such forward-looking statements and information, which are
qualified in their entirety by this cautionary statement. Except as
required by law, Revive disclaims any intention and assumes no
obligation to update or revise any forward-looking statements to
reflect actual results, whether as a result of new information,
future events, changes in assumptions, changes in factors affecting
such forward-looking statements or otherwise.
Contact:
Revive Therapeutics Ltd. Craig Leon Chief
Executive Officer Revive Therapeutics Ltd. Tel: (416) 272-5525
Email: craig@revivethera.com
Website: www.ReviveThera.com
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Revive Therapeutics (TSXV:RVV)
Historical Stock Chart
From Apr 2023 to Apr 2024